Importantly, the DR3 downstream signaling was not impaired in naïve nor activated ILC2s of the obese model, suggesting that DR3 remains a viable therapeutic target in the context of established metabolic syndrome. This evidence concerns the gene TNFRSF25 and metabolic syndrome.